Listing Highlights
Exclusive Building Restriction
Protected by an exclusive restriction clause preventing any competing pharmacy from operating in the host building or in a second medical building under the same landlord — a rare and durable competitive advantage.
Expanding Gross Margins
Despite a decline in top-line revenue over the past three fiscal years, gross margins have expanded significantly, reflecting improved dispensing efficiency and a favourable product mix shift.
40+ On-Site Physicians
Combined physician MSP billings across both protected buildings total approximately $28.7 million annually from over 40 practising physicians — a structural patient referral pipeline built into the lease.
Debt-Free, No Receivables
The business operates entirely debt-free with no accounts receivable outstanding. The clean balance sheet and cash-basis operations simplify due diligence and financing for a qualified buyer.
Long-Term Lease Available
Short-term extension is in place through June 2026 pending sale. The landlord has confirmed willingness to enter a long-term lease with a qualified new owner at current or negotiated rates.
Significant Growth Upside
Meaningful opportunity to increase prescription capture from on-site prescribers, expand clinical services including medication reviews and immunizations, and extend operating hours beyond current weekday schedule.
About This Opportunity
This pharmacy has operated continuously since 1992 within a large multi-tenant medical building in Burnaby, BC. It holds an exclusive restriction clause that prevents any competing pharmacy from operating in the host building or in a second medical building under the same landlord. Across both properties, combined physician MSP billings total approximately $28.7 million annually from over 40 practising physicians — a structural competitive moat embedded in the lease itself.
Revenue has declined over the past three fiscal years; however, gross margins have expanded significantly over the same period. The business operates debt-free with no accounts receivable outstanding, and the most recent fiscal year (October 2024 to September 2025) shows SDE and EBITDA of approximately $64,000 on a cash basis. Full financial analysis, SDE calculation, and supporting documentation are provided in the Confidential Information Memorandum.
The current lease is a short-term extension through June 2026, held in place pending the sale. The landlord has confirmed willingness to enter a long-term lease with a qualified incoming owner at current or negotiated rates. The asking price of $480,000 is structured as an asset sale and includes inventory estimated at approximately $38,000 at closing — representing an accessible entry point relative to the pharmacy’s protected market position and embedded referral network.
How to Access Full Details
Express Your Interest
Contact us using the inquiry form below or by email. All enquiries are held in strict confidence.
Sign the NDA
We send a straightforward non-disclosure agreement. Most buyers complete it within the hour.
Receive the CIM
Get the full Confidential Information Memorandum including financials within 24 hours of NDA execution.
Arrange a Site Visit
Meet the selling pharmacist on-site, review operations firsthand, and ask questions directly before proceeding.
Submit a Letter of Intent
Following the site visit, submit an LOI to proceed to formal due diligence and finalise terms with the seller.
Financial Details
Revenue, normalized EBITDA, and asking price are available to qualified buyers after completing our simple NDA process. Most buyers receive the full package within 24 hours.
Annual Revenue
🔒 NDA Required
Normalized EBITDA
🔒 NDA Required
Asking Price
🔒 Contact Us
Inquire About This Listing
All inquiries are confidential. We respond within one business day.
Your information is kept strictly confidential and is never shared without your consent.